Lumos Pharma, Inc. (LUMO) Tops Q3 EPS by 11c

Lumos Pharma, Inc. (NASDAQ: LUMO) reported Q3 EPS of ($1.04), $0.11 better than the analyst estimate of ($1.15). Revenue for the quarter came in at $7 thousand versus the consensus estimate of $225.4 thousand.

For earnings history and earnings-related data on Lumos Pharma, Inc. (LUMO) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Radnostix revenue falls 27% amid product recalls and FDA actions
• Omega Flex (OFLX) Tops Q2 EPS by 27c